130 related articles for article (PubMed ID: 23657159)
1. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.
Filppula AM; Tornio A; Niemi M; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2013 Sep; 94(3):383-93. PubMed ID: 23657159
[TBL] [Abstract][Full Text] [Related]
2. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans.
Itkonen MK; Tornio A; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT
Drug Metab Dispos; 2019 Apr; 47(4):377-385. PubMed ID: 30630815
[TBL] [Abstract][Full Text] [Related]
4. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
[TBL] [Abstract][Full Text] [Related]
5. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.
Tornio A; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Aug; 62(8):645-51. PubMed ID: 16832679
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.
Tornio A; Niemi M; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2007 May; 63(5):463-9. PubMed ID: 17333159
[TBL] [Abstract][Full Text] [Related]
7. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
Kim KA; Park SJ; Kim C; Park JY
Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
[TBL] [Abstract][Full Text] [Related]
8. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.
Karonen T; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2012 Feb; 73(2):257-67. PubMed ID: 21838784
[TBL] [Abstract][Full Text] [Related]
9. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.
Niemi M; Tornio A; Pasanen MK; Fredrikson H; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Jun; 62(6):463-72. PubMed ID: 16758263
[TBL] [Abstract][Full Text] [Related]
10. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.
Aquilante CL; Kosmiski LA; Bourne DW; Bushman LR; Daily EB; Hammond KP; Hopley CW; Kadam RS; Kanack AT; Kompella UB; Le M; Predhomme JA; Rower JE; Sidhom MS
Br J Clin Pharmacol; 2013 Jan; 75(1):217-26. PubMed ID: 22625877
[TBL] [Abstract][Full Text] [Related]
11. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.
Karonen T; Filppula A; Laitila J; Niemi M; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2010 Aug; 88(2):223-30. PubMed ID: 20592724
[TBL] [Abstract][Full Text] [Related]
12. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.
Nebot N; Crettol S; d'Esposito F; Tattam B; Hibbs DE; Murray M
Br J Pharmacol; 2010 Nov; 161(5):1059-69. PubMed ID: 20977456
[TBL] [Abstract][Full Text] [Related]
13. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.
Honkalammi J; Niemi M; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2012 May; 91(5):846-55. PubMed ID: 22472994
[TBL] [Abstract][Full Text] [Related]
14. The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast.
Karonen T; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2011 Feb; 67(2):151-5. PubMed ID: 20931329
[TBL] [Abstract][Full Text] [Related]
15. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers.
Ostrowicz A; Mikołajczak PL; Wierzbicka M; Boguradzki P
Acta Pol Pharm; 2014; 71(5):843-54. PubMed ID: 25362813
[TBL] [Abstract][Full Text] [Related]
17. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
Niemi M; Backman JT; Juntti-Patinen L; Neuvonen M; Neuvonen PJ
Br J Clin Pharmacol; 2005 Aug; 60(2):208-17. PubMed ID: 16042675
[TBL] [Abstract][Full Text] [Related]
18. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.
Shitara Y; Hirano M; Sato H; Sugiyama Y
J Pharmacol Exp Ther; 2004 Oct; 311(1):228-36. PubMed ID: 15194707
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
[TBL] [Abstract][Full Text] [Related]
20. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
Bruderer S; Petersen-Sylla M; Boehler M; Remeňová T; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2017 Dec; 83(12):2778-2788. PubMed ID: 28715853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
